39th Pharmacovigilance India 2025
39th Pharmacovigilance India 2025
19 & 20 November, 2025
Kohinoor Continental Hotel, Mumbai, India
5 Reasons to attend the event
Knowledge
Gain insights from experts, researchers, and professionals to stay updated on the latest pharma advancements.
Convenience
Attend sessions from anywhere, eliminating travel hassles while accessing high-quality content at your own pace.
Cutting-Edge Insights
Discover the latest trends, innovations, and breakthroughs shaping the future of the pharmaceutical industry.
Networking
Connect with peers, industry leaders, and collaborators to exchange ideas and explore new opportunities.
Practical Takeaways
Walk away with actionable strategies, real-world case studies, and learn best practices to implement in your work.
Knowledge
Gain insights from experts, researchers, and professionals on the latest pharma advancements.
An Agenda Made For You
High quality content that addresses your biggest challenges and uncovering hidden opportunities.
Cutting-Edge Insights
Explore the latest trends, innovations, and breakthroughs driving the future of the pharmaceutical industry.
Networking
Connect with peers, industry leaders, and collaborators to exchange ideas and explore new opportunities.
Practical Takeaways
Walk away with practical strategies, case studies, and proven best practices to apply in real-time.
Key Focus Areas
Event Speakers
Download Brochure
Event Schedule
Meet to learn and network with your conference colleagues.
08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues.
09:20 – Welcome address and Opening Remarks
09:40 – Keynote Address – Strategy for global PV system inspection readiness
INSPECTION READINESS
- Who needs to be ready
- Factors for consideration when supporting global inspections
- Common areas of non-compliance
- Management of responses
Speaker
RAJ K BHOGAL
Sr. Director, R&D Business Strategy & Operation
Jazz Pharmaceuticals (UK)
10:20 – Keynote Panel Discussion: Pharmacovigilance for Tomorrow: Navigating Challenges and Uncovering Opportunities
CHALLENGES & OPPORTUNITIES
- Tackle data overload and integration barriers in effective PV implementation.
- Examine the gaps between pre-marketing potential and post-marketing reality.
- Question if accelerated drug approvals compromise patient safety.
- Explore complexities in adopting AI and automation within PV systems.
- Discuss challenges in global literature monitoring for drug safety.
- Identify misconceptions, misuse, and underrecognized factors in ADR causation.
Moderator
Panellists
RAJENDRA KUMAR KASI
VP & Global Head – Pharmacovigilance
Glenmark
INDU NAMBIAR
Pharmacovigilance Lead & Country Safety Head
Sanofi
SAKSHI SHRIVASTAVA DESAI
Director, LMS regional Lead APAC
Johnson & Johnson
CHAITANYA KULKARNI
GM Pharmacovigilance
Marksans Pharma
11:10 – Morning Coffee/Tea & Discussion
11:40 – Panel Discussion: Patient-Centric Pharmacovigilance: Amplifying the Patient Voice in Drug Safety
PATIENT SAFETY
- Address unconscious bias in pharmacovigilance and explore mitigation strategies.
- Trace the shift from reactive to proactive patient safety models.
- Examine the role of patient input in signal detection and ADR prevention.
- Highlight the importance of protecting vulnerable patient groups.
- Discuss challenges in patient engagement, including tech access and language barriers.
- Emphasize the value of patient-reported outcomes in improving safety reporting and empowerment.
- Explore how public awareness enhances pharmacovigilance systems and data quality.
Moderator
VISHWAS SOVANI
Founder Director
Pharmawisdom
Panellists
VAIBHAV SALVI
Director & Head – Clinical Study Unit, India & South East Asia
Sanofi
SOURABH FULMALI
Global Medical Director – Respiratory
GSK
RENUKA NEOGI
Head & Deputy GM – Global Clinical Quality Management
Sun Pharma
JAMAL BAIG
Director, Drug Safety
SHRADDHA BHANGE
Senior Medical Safety Lead
Sandoz
12:40 – Networking luncheon
13:50 – Panel Discussion - The “Next Generation” risk management strategies
RISK MANAGEMENT
- Implementation and maintenance of RMP’s – Overcoming its challenges
- Potential analyzing of safety and risk signals in PV
- Strategies to minimize the risk measures – what are the new developments?
- Benefit/Risk ratio: the common Denominator
- Stakeholders in RMP – Communications must be improved
- Implementing a Risk-Based Monitoring Solution: Understanding the basics of a sustainable model
- Discussing about the strategies that support the PV from beginning to end
Moderator
VISHWAS SOVANI
Founder Director
Pharmawisdom
Panellists
GIRIJAA KADAM
Director – Global Safety Officer
Sanofi
JEROZE DALAL
Head of Clinical Operations, Governance & Risk Management
GSK
CHITRA BARGAJE
Sr.GM, Global Head PV, Drug Safety & Risk Management
Lupin
VASU MORLA
Global GCP/PV Auditor
Novartis
SUNIL HONKALAS
Senior DGM, Medical & PV
Fresenius Kabi
14:40 - Regulations on Pharmacovigilance in India
REGULATORY
- Regulations overview
- Practical scenario/ scope of improvement
- Interface of PV with regulatory
- Best practices across the global on PV practices
Speaker
MARTINA GOMES
Head, Reg Affairs – CH, South Asia
Bayer
15:10 – Afternoon Tea/Coffee
15:40 – External Service/Supplier Qualification: Challenges and Outcomes
Speaker
SHREYA DESHPANDE
Global Development Quality Manager
Novartis
16:10 – Panel Discussion: Outsourcing in Pharmacovigilance: Evolving Models, Strategic Partnerships & Global Impact
OUTSOURCING
- Explore outsourcing as a strategic tool to access expertise and scale operations.
- Evaluate the pros and cons of outsourcing pharmacovigilance activities.
- Understand key concerns around training, infrastructure, and partner readiness.
- Examine cost-efficiency and budget optimization through outsourced PV systems.
- Identify best practices for building strong, effective PV partnerships.
- Learn from successful collaborations that have enhanced global drug safety.
- Respond to rising case volumes with scalable, tech-enabled PV outsourcing models.
- Fostering quality culture in vendor environments
Moderator
ARUNIMA SEN
Associate VP, Product Safety and Risk Management
Viatris
Panellists
MUKESH GORI
Director Global Patient Safety
Amgen
RAHUL SOMANI
Head- Global Pharmacovigilance
Alkem Laboratories
ROHINI PANDEY
Regional PV Head- SEA
Abbott
VYNIE ANN RAO
Senior Manager
Glenmark
JYOTI KASHID
Manager, Global Patient Safety Operations
Lundbeck (Singapore)
17:00 - Closing remarks and end of conference
08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues.
09:20 – Welcome address and Opening Remarks
09:30 – Keynote Address – Strategy for global PV system inspection readiness
INSPECTION READINESS
- Who needs to be ready
- Factors for consideration when supporting global inspections
- Common areas of non-compliance
- Management of responses
Speaker
RAJ K BHOGAL
Sr. Director, R&D Business Strategy & Operation
Jazz Pharmaceuticals (UK)
10:10 – Keynote Panel Discussion: Pharmacovigilance for Tomorrow: Navigating Challenges and Uncovering Opportunities
CHALLENGES & OPPORTUNITIES
- Tackle data overload and integration barriers in effective PV implementation.
- Examine the gaps between pre-marketing potential and post-marketing reality.
- Question if accelerated drug approvals compromise patient safety.
- Explore complexities in adopting AI and automation within PV systems.
- Discuss challenges in global literature monitoring for drug safety.
- Identify misconceptions, misuse, and underrecognized factors in ADR causation.
Moderator
Panellists
RAJENDRA KUMAR KASI
VP & Global Head – Pharmacovigilance
Glenmark
INDU NAMBIAR
Pharmacovigilance Lead & Country Safety Head
Sanofi
SAKSHI SHRIVASTAVA DESAI
Director, LMS regional Lead APAC
Johnson & Johnson
KRUNAL DALAL
Head Medical Affairs
GSK
CHAITANYA KULKARNI
GM Pharmacovigilance
Marksans Pharma
11:00 – Morning Coffee/Tea & Discussion
11:30 – Panel Discussion: Patient-Centric Pharmacovigilance: Amplifying the Patient Voice in Drug Safety
PATIENT SAFETY
- Address unconscious bias in pharmacovigilance and explore mitigation strategies.
- Trace the shift from reactive to proactive patient safety models.
- Examine the role of patient input in signal detection and ADR prevention.
- Highlight the importance of protecting vulnerable patient groups.
- Discuss challenges in patient engagement, including tech access and language barriers.
- Emphasize the value of patient-reported outcomes in improving safety reporting and empowerment.
- Explore how public awareness enhances pharmacovigilance systems and data quality.
Moderator
VISHWAS SOVANI
Founder Director
Pharmawisdom
Panellists
VAIBHAV SALVI
Director & Head – Clinical Study Unit, India & South East Asia
Sanofi
SOURABH FULMALI
Global Medical Director – Respiratory
GSK
RENUKA NEOGI
Head & Deputy GM – Global Clinical Quality Management
Sun Pharma
JAMAL BAIG
Director, Drug Safety
SHRADDHA BHANGE
Senior Medical Safety Lead
Sandoz
12:20 - Topic TBC
For sponsorship opportunities please contact info@virtueinsight.com
12:50 – Networking luncheon
13:50 – Panel Discussion - The “Next Generation” risk management strategies
RISK MANAGEMENT
- Implementation and maintenance of RMP’s – Overcoming its challenges
- Potential analyzing of safety and risk signals in PV
- Strategies to minimize the risk measures – what are the new developments?
- Benefit/Risk ratio: the common Denominator
- Stakeholders in RMP – Communications must be improved
- Implementing a Risk-Based Monitoring Solution: Understanding the basics of a sustainable model
- Discussing about the strategies that support the PV from beginning to end
Moderator
VISHWAS SOVANI
Founder Director
Pharmawisdom
Panellists
GIRIJAA KADAM
Director – Global Safety Officer
Sanofi
JEROZE DALAL
Head of Clinical Operations, Governance & Risk Management
GSK
CHITRA BARGAJE
Sr.GM, Global Head PV, Drug Safety & Risk Management
Lupin
VASU MORLA
Global GCP/PV Auditor
Novartis
SUNIL HONKALAS
Senior DGM, Medical & PV
Fresenius Kabi
14:40 - Regulations on Pharmacovigilance in India
REGULATORY
- Regulations overview
- Practical scenario/ scope of improvement
- Interface of PV with regulatory
- Best practices across the global on PV practices
Speaker
MARTINA GOMES
Head, Reg Affairs – CH, South Asia
Bayer
15:10 – Afternoon Tea/Coffee
15:40 – External Service/Supplier Qualification: Challenges and Outcomes
Speaker
SHREYA DESHPANDE
Global Development Quality Manager
Novartis
16:10 – Panel Discussion: Outsourcing in Pharmacovigilance: Evolving Models, Strategic Partnerships & Global Impact
OUTSOURCING
- Explore outsourcing as a strategic tool to access expertise and scale operations.
- Evaluate the pros and cons of outsourcing pharmacovigilance activities.
- Understand key concerns around training, infrastructure, and partner readiness.
- Examine cost-efficiency and budget optimization through outsourced PV systems.
- Identify best practices for building strong, effective PV partnerships.
- Learn from successful collaborations that have enhanced global drug safety.
- Respond to rising case volumes with scalable, tech-enabled PV outsourcing models.
- Fostering quality culture in vendor environments
Moderator
ARUNIMA SEN
Associate VP, Product Safety and Risk Management
Viatris
Panellists
MUKESH GORI
Director Global Patient Safety
Amgen
RAHUL SOMANI
Head- Global Pharmacovigilance
Alkem Laboratories
ROHINI PANDEY
Regional PV Head- SEA
Abbott
VYNIE ANN RAO
Senior Manager
Glenmark
JYOTI KASHID
Manager, Global Patient Safety Operations
Lundbeck (Singapore)
17:00 - Closing remarks and end of conference
08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues.
09:30 - Materiovigilance in India: Strengthening Safety Structures for Medical Devices
MATERIOVIGILANCE
- Distinct vigilance systems are needed for medicines and medical devices.
- Device safety and performance are critical to protecting patient health.
Stakeholders must actively support post-market and market surveillance. - Underreporting of adverse events limits effective risk evaluation.
- Continuous safety monitoring ensures regulatory compliance and trust.
- India’s materiovigilance framework must evolve with global best practices.
Speaker
APARNA PRABHUNE
DGM – Regulatory Affairs
Wockhardt
10:00 – Panel Discussion - The Digital Future of Pharmacovigilance: Innovation, Intelligence & Integration
TECHNOLOGY
- Leverage big data and predictive modelling for early detection of safety signals.
- Utilize real-world data to enhance drug safety and operational excellence.
- Explore the growing role and impact of AI in pharmacovigilance.
- Integrate diverse data sources to strengthen data-driven safety decisions.
- Examine how digital tools are transforming communication across PV stakeholders.
- Assess the role of social media and digital platforms in adverse event reporting.
- Balance tech innovation with the need to uphold drug safety standards.
- Discuss innovation through drug repurposing and agile PV systems.
Moderator
RASHMI HEGDE
Former Executive Vice President Medical Affairs
GSK
Panellists
PRASAD DESHMUKH
Vice President & Head Pharmacovigilance
Cipla
BIJENDER MISHRA
Sr. GM & CISO
Alkem Laboratories
SUCHITA MORE
Associate Director Medical Affairs
MSD
DHWANI DHOLAKIA
Division Head – Information Technology
Otsuka Pharmaceutical
MEERA NAGARIA
Senior Data Scientist
Johnson & Johnson (Boston, USA)
10:50 – Morning Coffee/Tea & Discussion
11:20 – Panel Discussion- Managing Pharmacovigilance Audits & Inspections
AUDITS & INSPECTIONS
- Staying ahead in the race – Current trends for and future guidelines
- How to prepare and what to expect?
- Remote audits and inspections – Logistical issues
- PV Inspection readiness: Keeping on the right side of inspectors
- Methodologies, scope and oversight
- Boldly shaping the future
- What has this pandemic thought us towards audits and inspections?
Moderator
RAJ K BHOGAL
Sr. Director, R&D Business Strategy & Operations
Jazz Pharmaceuticals (UK)
Panellists
SUSHMITA KUSWA
Head Medical & Regulatory Affairs
Piramal
DEVANG PATEL
Head of Global Pharmacovigilance
Zydus Lifesciences
MUGDHA SHAH
PV Audit and Inspection Readiness Manager
Sanofi
SUNIL NIGHOT
Manager, ICSR Quality
Kenvue (Division of J&J)
12:10 - Explainable AI: Why you see What you see
Break the black box: Generating explainability behind predictive models is quite a challenge. Hence to mitigate it, we have developed a novel technique which helps us understand the relationship between the input and the output in a more human understandable format.
Speaker
MEERA NAGARIA
Senior Data Scientist
Johnson & Johnson (Boston, USA)
12:40 – Networking luncheon
13:50 – Panel Discussion - Why RWD and RWE is crucial for Pharmacovigilance
RWD / RWE
- Importance of real-world data for answering questions
- Benefits and challenges of evidence derived from real world sources
- Real World Evidence: How Does its Use challenge quality and compliance programs?
Obtaining patient-centric using RWE - Implications of RWE for Quality and Compliance
- What are complications that will rise by inserting new data source? Breakup in data?
- Identify the challenges involved in incorporating real world evidence into a structured benefit-risk assessment.
Moderator
KAVITA LAMROR
Partner, RWE & Digital Transformation
Maxis Clinical Sciences
Panellists
PRATIK SHAH
Senior Vice President and Head of Medical Affair
Bharat Serums and Vaccines
SANTOSH TAUR
Director Medical Affairs, Ex-Chair, RWE Council, ISCR
Pfizer
PRTHWIJIT KUNDU
Chief Medical Officer NCE NDD
Wockhardt
HARSHAD MALVE
Medical Head – Self-Care & Operations
Kenvue
MAYUR MAYBHATE
Head Medical Affairs
Alkem Laboratories
14:40 – Pharmacovigilance in South Asia: A Regional Perspective on Drug Safety Challenge
Overcoming underreporting of ADRs due to cultural and socioeconomic factors. Developing community-centric approaches to improve PV participation.
Speaker
ANUJA JAWALE
Associate Director – Area Safety Head – India and South Asia Cluster
Kenvue (Division of J&J)
15:10 – Afternoon Tea/ Coffee & Networking
15:40 - Panel Discussion – Regulatory: Current Scenario & Key Reforms Needed to Ensure Safer Drugs for Patients
REGULATORY
As the global pharmacovigilance landscape continues to evolve, the regulatory environment remains both a guiding framework and a formidable challenge. This session will explore the current regulatory scenario and assess what reforms are needed to ensure patient safety without stifling innovation.
- Navigating global PV compliance in an increasingly complex regulatory environment
- Adapting to intensified safety regulations and aligning with international expectations
- Leveraging real-world data and evidence to support regulatory decisions
- Addressing challenges in PV and MV reporting and submission frameworks
- Building inspection-ready systems to manage evolving and diverse regulatory demands
- Balancing global regulatory convergence with local adaptability and reduced industry burden
Moderator
OMPRAKASH S. SADHWANI
Former Joint Commissioner & Controlling Authority
FDA (Maharashtra State)
Panellists
RAHUL GUPTA
Senior Vice President, Regulatory Affairs
USV
GEETA SHANBHAG
VP – PV & Medico-Regulatory Affairs
Ipca Laboratories
PRABHAT SINHA
Director Government & Public Affairs
Boehringer Ingelheim
SHIRAZ KANDAWALLA
Associate Director
Ferring Pharmaceuticals
KHOKAN DEBNATH
Sr. GM – Regulatory Affairs, Clinical Operations, PV & QA
Wockhardt
16:50 – Lucky Draw / Closing remarks & end of conference
08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues.
09:30 - Materiovigilance in India: Strengthening Safety Structures for Medical Devices
MATERIOVIGILANCE
- Distinct vigilance systems are needed for medicines and medical devices.
- Device safety and performance are critical to protecting patient health.
Stakeholders must actively support post-market and market surveillance. - Underreporting of adverse events limits effective risk evaluation.
- Continuous safety monitoring ensures regulatory compliance and trust.
- India’s materiovigilance framework must evolve with global best practices.
Speaker
APARNA PRABHUNE
DGM – Regulatory Affairs
Wockhardt
10:00 – Panel Discussion - The Digital Future of Pharmacovigilance: Innovation, Intelligence & Integration
TECHNOLOGY
- Leverage big data and predictive modelling for early detection of safety signals.
- Utilize real-world data to enhance drug safety and operational excellence.
- Explore the growing role and impact of AI in pharmacovigilance.
- Integrate diverse data sources to strengthen data-driven safety decisions.
- Examine how digital tools are transforming communication across PV stakeholders.
- Assess the role of social media and digital platforms in adverse event reporting.
- Balance tech innovation with the need to uphold drug safety standards.
- Discuss innovation through drug repurposing and agile PV systems.
Moderator
RASHMI HEGDE
Former Executive Vice President Medical Affairs
GSK
Panellists
PRASAD DESHMUKH
Vice President & Head Pharmacovigilance
Cipla
BIJENDER MISHRA
Sr. GM & CISO
Alkem Laboratories
SUCHITA MORE
Associate Director Medical Affairs
MSD
DHWANI DHOLAKIA
Division Head – Information Technology
Otsuka Pharmaceutical
MEERA NAGARIA
Senior Data Scientist
Johnson & Johnson (Boston, USA)
10:50 – Morning Coffee/Tea & Discussion
11:20 – Panel Discussion- Managing Pharmacovigilance Audits & Inspections
AUDITS & INSPECTIONS
- Staying ahead in the race – Current trends for and future guidelines
- How to prepare and what to expect?
- Remote audits and inspections – Logistical issues
- PV Inspection readiness: Keeping on the right side of inspectors
- Methodologies, scope and oversight
- Boldly shaping the future
- What has this pandemic thought us towards audits and inspections?
Moderator
RAJ K BHOGAL
Sr. Director, R&D Business Strategy & Operations
Jazz Pharmaceuticals (UK)
Panellists
SUSHMITA KUSWA
Head Medical & Regulatory Affairs
Piramal
DEVANG PATEL
Head of Global Pharmacovigilance
Zydus Lifesciences
MUGDHA SHAH
PV Audit and Inspection Readiness Manager
Sanofi
SUNIL NIGHOT
Manager, ICSR Quality
Kenvue (Division of J&J)
12:10 - Explainable AI: Why you see What you see
Break the black box: Generating explainability behind predictive models is quite a challenge. Hence to mitigate it, we have developed a novel technique which helps us understand the relationship between the input and the output in a more human understandable format.
Speaker
MEERA NAGARIA
Senior Data Scientist
Johnson & Johnson (Boston, USA)
12:40 – Networking luncheon
13:50 – Panel Discussion - Why RWD and RWE is crucial for Pharmacovigilance
RWD / RWE
- Importance of real-world data for answering questions
- Benefits and challenges of evidence derived from real world sources
- Real World Evidence: How Does its Use challenge quality and compliance programs?
Obtaining patient-centric using RWE - Implications of RWE for Quality and Compliance
- What are complications that will rise by inserting new data source? Breakup in data?
- Identify the challenges involved in incorporating real world evidence into a structured benefit-risk assessment.
Moderator
KAVITA LAMROR
Partner, RWE & Digital Transformation
Maxis Clinical Sciences
Panellists
PRATIK SHAH
Senior Vice President and Head of Medical Affair
Bharat Serums and Vaccines
SANTOSH TAUR
Director Medical Affairs, Ex-Chair, RWE Council, ISCR
Pfizer
PRTHWIJIT KUNDU
Chief Medical Officer NCE NDD
Wockhardt
HARSHAD MALVE
Medical Head – Self-Care & Operations
Kenvue
MAYUR MAYBHATE
Head Medical Affairs
Alkem Laboratories
14:40 – Pharmacovigilance in South Asia: A Regional Perspective on Drug Safety Challenge
Overcoming underreporting of ADRs due to cultural and socioeconomic factors. Developing community-centric approaches to improve PV participation.
Speaker
ANUJA JAWALE
Associate Director – Area Safety Head – India and South Asia Cluster
Kenvue (Division of J&J)
15:10 – Afternoon Tea/ Coffee & Networking
15:40 - Panel Discussion – Regulatory: Current Scenario & Key Reforms Needed to Ensure Safer Drugs for Patients
REGULATORY
As the global pharmacovigilance landscape continues to evolve, the regulatory environment remains both a guiding framework and a formidable challenge. This session will explore the current regulatory scenario and assess what reforms are needed to ensure patient safety without stifling innovation.
- Navigating global PV compliance in an increasingly complex regulatory environment
- Adapting to intensified safety regulations and aligning with international expectations
- Leveraging real-world data and evidence to support regulatory decisions
- Addressing challenges in PV and MV reporting and submission frameworks
- Building inspection-ready systems to manage evolving and diverse regulatory demands
- Balancing global regulatory convergence with local adaptability and reduced industry burden
Moderator
OMPRAKASH S. SADHWANI
Former Joint Commissioner & Controlling Authority
FDA (Maharashtra State)
Panellists
RAHUL GUPTA
Senior Vice President, Regulatory Affairs
USV
GEETA SHANBHAG
VP – PV & Medico-Regulatory Affairs
Ipca Laboratories
PRABHAT SINHA
Director Government & Public Affairs
Boehringer Ingelheim
SHIRAZ KANDAWALLA
Associate Director
Ferring Pharmaceuticals
KHOKAN DEBNATH
Sr. GM – Regulatory Affairs, Clinical Operations, PV & QA
Wockhardt
16:50 – Lucky Draw / Closing remarks & end of conference
Download Brochure
Event Sponsors
We wouldn’t be able to host our conferences without help from these amazing companies. A huge thanks to all our sponsors and partners!
Exhibitors
Conceptualized By
- Phone:+91 44 42108101
- Email:info@virtueinsight.com
Supported By
- Phone:+91 89250 31783
- Email:info@allconferencealert.com
Event Testimonials
A huge thanks to all our sponsors, attendees and partners!
“The conference was a remarkable opportunity for networking with other experts in our field. Every session was enlightening, and I’m eager to apply what I learned to my business right away. As I noted during the event, your dedication is commendable! You’ve gathered an extraordinary group of speakers, and the empowering connections made with fellow pharmacovigilance colleagues on the panels and in keynote speeches were truly inspiring.”
It was very beneficial & effective conference. Got an opportunity to meet members from PV world & learn new areas if AI, Drug Development. Would defiantly visit again if given an opportunity.
A great platform to understand the current practices & situation all across the industry, as well as individual approach of each company toward the goal of patient safety
I would like to appreciate the efforts & initiative of Virtue Insight in organising the 17th Pharmacovigilance 2018 dedicated conference. The conference was very much interesting & was a good platform for networking, It was well organised, very insightful & a informative conference. The whole conference was more lively & in particular the panel discussions. This should happen regularly to keep PV professional updated. I have enjoyed the whole conference very much.
Had wonderful opportunity to share current challenges with Regulatory aspects of Pharmacovigilance. Very informative conference and very much needed to educated all the stake holders considering current scenario of Pharmacovigilance within our regulatory. We had very interesting discussion on CRO role for end to end Pharmacovigilance. I enjoy the way Dr. Milind handled our Panel discussion.
Very nicely managed. Good Speakers & content. Cooperative and convenient venue. Nice management of time. Good opportunity for networking
The Venue, key speakers included from big pharma companies & CROs has been perfect for the topic of panel discussion
The session was knowledge transfer/sharing and valuable too
Panel discussions are very interactive as well as address real world and practical issues
A commercial knowledge venture explored several areas under the topic. Very good and Professional speakers.
This kind of conference is very important for younger generations and professionals to get mere awareness and day to day updates in markets
The content of the conference is always good. Good to see speakers from regulatory authorities. Always delighted to attend your conference.
Great conference, great people, great presentations, - thanks to you and Virtue Insight team for running everything smoothly!
Kudos to the organizing team – you did it again! A very good networking opportunity, highly recommending this to young professionals as well. Excellent panel discussions and presentations, with a variety of topic of interest, all very actual in the field of pharmacovigilance and beyond. Also not to neglect: great venue and food.
I enjoyed the conference. It was very well organised and knowledgeable. It gave me a scope to understand the current affairs in the Pharmacovigilance industry and also got a chance to meet the experts in this field.
It's my pleasure as a speaker at the 29th Pharmacovigilance India 2022 from Virtue Insight Conference, It was a great experience sharing knowledge with Industry experts, interacting with leaders, speakers, professionals, guests, and spreading awareness about Pharmacovigilance in society with learning new things. Many thanks for the support and for encouraging all to be more vigilant on medicines and the Healthcare system by organizing excellent conferences.
Well organized & good topics covered by experienced speakers
The overall sessions were good with enlightening information
It’s a very good place to connect with all PV professionals from different sponsors from India includes some top most
Pricing Details
Exclusive Offer — 3 Delegates for the Price of 2!
STANDARD PRICE — INR 21,000 + GST (18%) PER DELEGATE
You can simply email or call and book your conference delegate seats on:
TEL: + 91 44 42108101 (or) Email — bookings@virtueinsight.com
CONFERENCE SPONSOR & EXHIBITION STALL
Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to:
TEL: + 91 44 42108101 (or) Email — bookings@virtueinsight.com
Download Brochure
Venue Details
The venue is easily accessible, well-equipped with modern amenities, and offers a comfortable, professional setting for all attendees.
Venue –
Kohinoor Continental Hotel, Mumbai, India
Andheri Kurla Road, Andheri ( E )
Mumbai 400059 – India
91 22 66919000 / 91 22 28209999
Venue
Kohinoor Continental Hotel, Mumbai,
India
Andheri Kurla Road, Andheri ( E )
Mumbai 400059 – India
91 22 66919000 / 91 22 28209999





